Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.
3区 · 医学
作者: Loukia G Karacosta ; John C Fisk ; Joseph Jessee ; Swetha Tati ; Bradley Turner ; Diala Ghazal ; Rachel Ludwig ; Holly Johnson ; Julia Adams ; Munawwar Sajjad ; Steven Koury ; Rene Roy ; James R Olson ; Kate Rittenhouse-Olson
The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of human tumor and normal tissue microarrays and in vivo biodistribution and imaging by micro-positron emission tomography imaging in breast and lung tumor models in mice. The IHC analysis detailed herein is the comprehensive biological analysis of the tumor specificity of JAA-F11 antibody performed as JAA-F11 is progressing towards preclinical safety testing and clinical trials. Wide tumor reactivity of JAA-F11, relative to the matched mouse IgG3 (control), was observed in 85% of 1269 cases of breast, lung, prostate, colon, bladder, and ovarian cancer. Staining on tissues from breast cancer cases was similar regardless of hormonal or Her2 status, and this is particularly important in finding a target on the currently untargetable triple-negative breast cancer subtype. Humanization of JAA-F11 was recently carried out as explained in a companion paper "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" (Neoplasia 19: 716-733, 2017), and it was confirmed that humanization did not affect chemical specificity. IHC studies with humanized JAA-F11 showed similar binding to human breast tumor tissues. In vivo imaging and biodistribution studies in a mouse syngeneic breast cancer model and in a mouse-human xenograft lung cancer model with humanized 124I- JAA-F11 construct confirmed in vitro tumor reactivity and specificity. In conclusion, the tumor reactivity of JAA-F11 supports the continued development of JAA-F11 as a targeted cancer therapeutic for multiple cancers, including those with unmet need.
2018-01-01·Neoplasia (New York, N.Y.)2区 · 医学
Corrigendum to "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" [Neoplasia 19.9 (2017) 716-733].
2区 · 医学
作者: Swetha Tati ; John C Fisk ; Julia Abdullah ; Loukia Karacosta ; Taylor Chrisikos ; Padraic Philbin ; Susan Morey ; Diala Ghazal ; Fatma Zalzala ; Joseph Jessee ; Sally Quataert ; Stephen Koury ; David Moreno ; Jing Ying Eng ; Vladislav V Glinsky ; Olga V Glinskii ; Muctarr Sesay ; Anthony W Gebhard ; Karamverr Birthare ; James R Olson ; Kate Rittenhouse-Olson
2017-09-01·Neoplasia (New York, N.Y.)2区 · 医学
Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.
2区 · 医学
作者: Swetha Tati ; John C Fisk ; Julia Abdullah ; Loukia Karacosta ; Taylor Chrisikos ; Padraic Philbin ; Susan Morey ; Diala Ghazal ; Fatma Zazala ; Joseph Jessee ; Sally Quataert ; Stephen Koury ; David Moreno ; Jing Ying Eng ; Vladislav V Glinsky ; Olga V Glinskii ; Muctarr Sesay ; Anthony W Gebhard ; Karamveer Birthare ; James R Olson ; Kate Rittenhouse-Olson
JAA-F11 is a highly specific mouse monoclonal to the Thomsen-Friedenreich Antigen (TF-Ag) which is an alpha-O-linked disaccharide antigen on the surface of ~80% of human carcinomas, including breast, lung, colon, bladder, ovarian, and prostate cancers, and is cryptic on normal cells. JAA-F11 has potential, when humanized, for cancer immunotherapy for multiple cancer types. Humanization of JAA-F11, was performed utilizing complementarity determining regions grafting on a homology framework. The objective herein is to test the specificity, affinity and biology efficacy of the humanized JAA-F11 (hJAA-F11). Using a 609 target glycan array, 2 hJAA-F11 constructs were shown to have excellent chemical specificity, binding only to TF-Ag alpha-linked structures and not to TF-Ag beta-linked structures. The relative affinity of these hJAA-F11 constructs for TF-Ag was improved over the mouse antibody, while T20 scoring predicted low clinical immunogenicity. The hJAA-F11 constructs produced antibody-dependent cellular cytotoxicity in breast and lung tumor lines shown to express TF-Ag by flow cytometry. Internalization of hJAA-F11 into cancer cells was also shown using a surface binding ELISA and confirmed by immunofluorescence microscopy. Both the naked hJAA-F11 and a maytansine-conjugated antibody (hJAA-F11-DM1) suppressed in vivo tumor progression in a human breast cancer xenograft model in SCID mice. Together, our results support the conclusion that the humanized antibody to the TF-Ag has potential as an adjunct therapy, either directly or as part of an antibody drug conjugate, to treat breast cancer, including triple negative breast cancer which currently has no targeted therapy, as well as lung cancer.